Hepatic glucose production machinery (HGP machinery)

The hepatic glucose production machinery encompasses the integrated metabolic pathways in liver hepatocytes responsible for glycogenolysis and gluconeogenesis, which generate glucose during fasting to maintain blood glucose homeostasis for organs like the brain and red blood cells. Key components include enzymes such as glucose-6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase (FBPase), and glucokinase (GK), alongside transporters like GLUT2, with tight regulation by substrate cycles (e.g., glucose/G6P, F6P/F1,6BP) and glycogen synthase/phosphorylase. Hormonal control is central: insulin suppresses production via IRS/PI3K/Akt/FoxO1 signaling to promote glycogen storage and inhibit gluconeogenic gene expression, while glucagon, catecholamines, and glucocorticoids activate it through cAMP/PKA/CREB/PGC-1α pathways, often enhanced by transcriptional regulators like HNF-4α, CREBH, and PPARα. In type 2 diabetes, dysregulated HGP contributes to fasting hyperglycemia due to hepatic insulin resistance and excessive glucagon action, making this machinery a prime therapeutic target. Drugs like metformin indirectly suppress it by activating AMPK to reduce gluconeogenic gene expression, while emerging agents target specific enzymes or receptors (e.g., glucagon antagonists) to restore balance, though challenges include avoiding hypoglycemia and managing off-target effects on energy metabolism.

Other names

hepatic glucose production (HGP)HGP pathwayshepatic gluconeogenesis and glycogenolysis machinery

Inhibition of gluconeogenic enzymes (e.g., PEPCK, G6Pase, FBPase), Activation of insulin signaling to suppress FoxO1 and PGC-1α, Reduction of glucagon signaling via PKA/CREB pathway, Allosteric modulation of key enzymes like pyruvate carboxylase